{
    "ticker": "VNDA",
    "name": "Vanda Pharmaceuticals Inc.",
    "description": "Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to address unmet medical needs. Founded in 2003 and headquartered in Washington, D.C., Vanda is committed to improving the lives of patients through cutting-edge research and drug development. The company is known for its flagship product, HETLIOZ (tasimelteon), which is approved for the treatment of non-24-hour sleep-wake disorder (Non-24), a condition that affects blind individuals and disrupts their circadian rhythms. In addition to HETLIOZ, Vanda is also developing other treatments, including tradipitant for conditions such as gastroparesis and chronic pruritus, showcasing its dedication to addressing various neurological and gastrointestinal disorders. Vanda's research and development efforts are guided by a patient-centric approach, and the company collaborates with various stakeholders in the healthcare ecosystem to enhance the understanding and management of complex diseases. With a robust pipeline and a focus on scientific excellence, Vanda Pharmaceuticals is well-positioned to contribute to the advancement of healthcare and improve patient outcomes.",
    "industry": [
        "Pharmaceuticals",
        "Biotechnology"
    ],
    "headquarters": "Washington, D.C., USA",
    "founded": "2003",
    "website": "https://www.vandapharmaceuticals.com",
    "ceo": "James Patrick Kelly",
    "social_media": {
        "twitter": "https://twitter.com/VandaPharma",
        "linkedin": "https://www.linkedin.com/company/vanda-pharmaceuticals/"
    },
    "investor_relations": "https://investors.vandapharmaceuticals.com",
    "key_executives": [
        {
            "name": "James Patrick Kelly",
            "position": "CEO"
        },
        {
            "name": "Richard L. L. L. D. M. V. G. M. De Silva",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Pharmaceutical Products",
            "products": [
                "HETLIOZ",
                "tradipitant"
            ]
        }
    ],
    "seo": {
        "meta_title": "Vanda Pharmaceuticals Inc. | Innovative Therapeutics for Unmet Medical Needs",
        "meta_description": "Explore Vanda Pharmaceuticals Inc., a biopharmaceutical company dedicated to developing innovative treatments for complex medical conditions. Learn about our flagship products and ongoing research.",
        "keywords": [
            "Vanda Pharmaceuticals",
            "HETLIOZ",
            "biopharmaceuticals",
            "non-24-hour sleep-wake disorder",
            "tradipitant",
            "neurological disorders"
        ]
    },
    "faq": [
        {
            "question": "What is Vanda Pharmaceuticals known for?",
            "answer": "Vanda Pharmaceuticals is known for developing innovative therapeutics, notably HETLIOZ for non-24-hour sleep-wake disorder."
        },
        {
            "question": "Who is the CEO of Vanda Pharmaceuticals?",
            "answer": "James Patrick Kelly is the CEO of Vanda Pharmaceuticals Inc."
        },
        {
            "question": "Where is Vanda Pharmaceuticals headquartered?",
            "answer": "Vanda Pharmaceuticals is headquartered in Washington, D.C., USA."
        },
        {
            "question": "What are Vanda's main products?",
            "answer": "Vanda's main products include HETLIOZ and tradipitant."
        },
        {
            "question": "When was Vanda Pharmaceuticals founded?",
            "answer": "Vanda Pharmaceuticals was founded in 2003."
        }
    ],
    "competitors": [
        "VRTX",
        "ALNY",
        "SAGE",
        "PTCT"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "ABBV",
        "MRNA"
    ]
}